Log in
Enquire now
Akero Therapeutics

Akero Therapeutics

Akero Therapeutics is a Cambridge, Massachusetts-based biotechnology company focused on reversing the NASH epidemic by restoring the body's metabolism to a balanced state.

OverviewStructured DataIssuesContributors

Contents

akerotx.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Engineering
Engineering
Therapeutics
Therapeutics
Biomedical engineering
Biomedical engineering
Chemistry
Chemistry
Drug metabolism
Drug metabolism
Enzyme kinetics
Enzyme kinetics
Pharmacokinetics
Pharmacokinetics
...
Location
San Francisco
San Francisco
South San Francisco, California
South San Francisco, California
0
Cambridge, Massachusetts
Cambridge, Massachusetts
CEO
‌
Jonathan Young
0
Founder
‌
Jonathan Young
0
‌
Tim Rolph
0
Pitchbook URL
pitchbook.com/profiles...230051-26
Legal Name
Akero Therapeutics, Inc.
Number of Employees (Ranges)
11 – 50
Email Address
info@akerotx.com
Phone Number
+165048764880
Full Address
601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080, USA0
CIK Number
1,744,6590
Place of Incorporation
Delaware
Delaware
0
Investors
Rock Springs Capital
Rock Springs Capital
Boxer Capital
Boxer Capital
Redmile Group
Redmile Group
venBio
venBio
Cormorant Asset Management
Cormorant Asset Management
Janus Henderson Investors
Janus Henderson Investors
Biotechnology Value Fund (BVF Partners)
Biotechnology Value Fund (BVF Partners)
Atlas Venture
Atlas Venture
...
Founded Date
2017
Total Funding Amount (USD)
135,000,000
Latest Funding Round Date
December 12, 2018
Stock Symbol
AKRO0
Exchange
Nasdaq
Nasdaq
0
Board of Directors
‌
Mark Iwicki
0
‌
Jane Pritchett Henderson
0
‌
Tom Heyman
0
‌
Seth L. Harrison
0
Latest Funding Type
Series B
Series B
Country
United States
United States
0

Other attributes

Company Operating Status
Active
Contact Page URL
akerotx.com/contact/
SIC Code
2,8340
Ticker Symbol
AKRO

Akero Therapeutics is a biotechnology company. Akero's mission is to reverse the course of serious metabolic diseases and change patients’ lives. The company's dedicated team is laser-focused on reversing the NASH epidemic by restoring the metabolism of the body to a balanced state.

Its multi-modal drug, efruxifermin (EFX), mimics FGF21 to face the many facets of NASH, and clinical data suggests that it possesses the potential to become a foundational NASH monotherapy.

Akero is involved in R&D which is solely focused on developing medicines to reverse the escalating NASH epidemic, a disease that involves the whole body, and requires treatment of the imbalanced metabolism. This R&D approach is applied to address the underlying metabolic causes and the downstream pathological pathways leading to liver cirrhosis, liver failure and death.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Akero Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.